DK1639112T3 - Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf - Google Patents
Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf Download PDFInfo
- Publication number
- DK1639112T3 DK1639112T3 DK04776236.4T DK04776236T DK1639112T3 DK 1639112 T3 DK1639112 T3 DK 1639112T3 DK 04776236 T DK04776236 T DK 04776236T DK 1639112 T3 DK1639112 T3 DK 1639112T3
- Authority
- DK
- Denmark
- Prior art keywords
- promoter
- seq
- actin
- hamster
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
Claims (18)
1. Isoleret β-actin-promotor, der er udvalgt blandt nukleotidsekvenserne ifølge SEQ ID NO: 1 eller 3 eller en variant deraf, der har promotoraktivitet, hvor varianten er en nukleotidsekvens, der har mindst 95 % identitet med en nukleotidsekvens ifølge SEQ ID NO: 1 eller 3 over den fulde længde af denne referencesekvens.
2. Isoleret promotor ifølge krav 1, hvor promotoren er nukleotidsekvensen ifølge SEQ ID NO: 1 eller en variant deraf, der har promotoraktivitet, hvor varianten er en nukleotidsekvens, der har mindst 95 % identitet med nukleotidsekvensen ifølge SEQ ID NO: 1 over den fulde længde af SEQ ID NO: 1.
3. Isoleret promotor ifølge krav 2, hvor promotoren er en variant af nukleotidsekvensen ifølge SEQ ID NO: 1, og hvor varianten er en nukleotidsekvens, der har mindst 97 % identitet med nukleotidsekvensen ifølge SEQ ID NO: 1 over den fulde længde af SEQ ID NO: 1.
4. Isoleret promotor ifølge krav 1, hvor promotoren er nukleotidsekvensen ifølge SEQ ID NO: 3 eller en variant deraf, der har promotoraktivitet, hvor varianten er en nukleotidsekvens, der har mindst 95 % identitet med nukleotidsekvensen ifølge SEQ ID NO: 3 over den fulde længde af SEQ ID NO: 3.
5. Isoleret promotor ifølge krav 4, hvor promotoren er en variant af nukleotidsekvensen ifølge SEQ ID NO: 3, og hvor varianten er en nukleotidsekvens, der har mindst 97 % identitet med nukleotidsekvensen ifølge SEQ ID NO: 3 over den fulde længde af SEQ ID NO: 3.
6. Vektor, der omfatter promotoren ifølge et hvilket som helst af kravene 1-3, 4 eller 5.
7. Vektor ifølge krav 6, hvor vektoren omfatter promotoren ifølge krav 2 eller krav 3.
8. Vektor ifølge krav 6 eller krav 7, hvor promotoren er operabelt koblet til en heterolog nukleinsyre.
9. Vektor ifølge krav 8, hvor den heterologe nukleinsyre koder for et terapeutisk protein.
10. Vektor ifølge krav 9, hvor det terapeutiske protein er udvalgt fra gruppen, der består af syre-sphingomyelinase, a- glucosidase og vævsplasminogenaktivator.
11. Værtscelle, der er transficeret med vektoren ifølge et hvilket som helst af kravene 6-10.
12. Værtscelle ifølge krav 11, hvilken værtscelle er en kinesisk hamsterovarie (CHO)-celle.
13. Fremgangsmåde til fremstilling af et protein, hvilken fremgangsmåde omfatter: (a) dyrkning af en værtscelle, der er transficeret med en vektor, der omfatter en promotor ifølge et hvilket som helst af af kravene 1-3 eller 5, hvor promotoren er operabelt koblet til et nukleinsyremolekyle, der koder for proteinet; og (b) indvinding af proteinet.
14. Fremgangsmåde ifølge krav 13, hvor proteinet er et antistof.
15. Fremgangsmåde ifølge krav 14, hvor antistoffet binder til et medlem af TGF-β-ίamilien.
16. Fremgangsmåde ifølge krav 13, hvor proteinet er et terapeutisk protein.
17. Fremgangsmåde ifølge krav 16, hvor det terapeutiske protein er udvalgt fra gruppen, der består af syre-sphingomyelinase, α-glucosidase og vævsplasminogenaktivator.
18. Non-humant transgent dyr, der omfatter vektoren ifølge et hvilket som helst af kravene 6-10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48076803P | 2003-06-24 | 2003-06-24 | |
PCT/US2004/017422 WO2005000888A2 (en) | 2003-06-24 | 2004-06-24 | NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1639112T3 true DK1639112T3 (da) | 2015-07-06 |
Family
ID=33551946
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10186322.3T DK2332972T3 (da) | 2003-06-24 | 2004-06-24 | Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf |
DK04776236.4T DK1639112T3 (da) | 2003-06-24 | 2004-06-24 | Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10186322.3T DK2332972T3 (da) | 2003-06-24 | 2004-06-24 | Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf |
Country Status (15)
Country | Link |
---|---|
US (5) | US7423135B2 (da) |
EP (3) | EP1639112B1 (da) |
JP (2) | JP4917886B2 (da) |
CN (5) | CN107058313A (da) |
BR (1) | BRPI0411843B8 (da) |
CA (1) | CA2530020A1 (da) |
CY (1) | CY1121580T1 (da) |
DK (2) | DK2332972T3 (da) |
ES (2) | ES2665493T3 (da) |
HU (2) | HUE025374T2 (da) |
IL (3) | IL172653A0 (da) |
PL (1) | PL2332972T3 (da) |
PT (1) | PT2332972T (da) |
SI (1) | SI2332972T1 (da) |
WO (1) | WO2005000888A2 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2332972T3 (da) * | 2003-06-24 | 2018-04-23 | Genzyme Corp | Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf |
JP4573775B2 (ja) * | 2003-07-29 | 2010-11-04 | 一般財団法人化学及血清療法研究所 | 組換えフィブリノゲン高産生細胞の作製方法及び高産生細胞 |
WO2005054467A1 (ja) * | 2003-12-03 | 2005-06-16 | Chugai Seiyaku Kabushiki Kaisha | 哺乳類βアクチンプロモーターを利用した発現系 |
PT2064337E (pt) * | 2006-09-20 | 2012-07-26 | Genzyme Corp | Sistema à base de facs e proteína repórter para o desenvolvimento de elevado desempenho de proteínas terapêuticas |
CA2676651A1 (en) * | 2007-01-25 | 2008-07-31 | Amprotein Corporation | Use of chick beta actin gene intron-1 |
WO2009155950A1 (en) | 2008-06-27 | 2009-12-30 | King Faisal Specialist Hospital And Research Centre | Cloning-free method of generating transcriptionally and post-transcriptionally controllable expression active linear reporter constructs |
KR101038126B1 (ko) | 2010-11-30 | 2011-05-31 | 주식회사 엘지생명과학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
WO2012145644A1 (en) | 2011-04-22 | 2012-10-26 | Genzyme Corporation | Modified acid alpha glucosidase with accelerated processing |
TW201632625A (zh) | 2011-11-28 | 2016-09-16 | 第一三共股份有限公司 | 源自人類基因的啟動子 |
EP3871688B1 (en) | 2012-05-03 | 2024-03-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of pompe disease |
WO2016172442A1 (en) | 2015-04-23 | 2016-10-27 | Quest Diagnostics Investments Incorporated | Mlh1 methylation assay |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
IL309289A (en) | 2015-10-09 | 2024-02-01 | Genzyme Corp | Improved combustion technology (flow cytometry that reduces the expression of the reporter) for rapid sorting of substances in high masses |
CL2016001661A1 (es) * | 2016-06-29 | 2017-03-03 | Univ Chile | Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes. |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
US20180119192A1 (en) | 2016-10-07 | 2018-05-03 | Genzyme Corporation | Early post-transfection isolation of cells (epic) for biologics production |
WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
CN109371106A (zh) * | 2018-12-18 | 2019-02-22 | 湖南农业大学 | 赤眼鳟β-肌动蛋白基因cDNA全长序列、扩增引物及扩增方法 |
CN114269674A (zh) | 2019-08-21 | 2022-04-01 | 因温特奥股份公司 | 扶手检查装置 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US480768A (en) | 1892-08-16 | Paper-jogger | ||
AU762993C (en) * | 1998-02-26 | 2004-06-10 | Pioneer Hi-Bred International, Inc. | Constitutive maize promoters |
CA2365961A1 (en) * | 1999-04-06 | 2000-10-12 | The Regents Of The University Of California | Human neurogenin 3-encoding nucleotide sequences |
JP4119061B2 (ja) * | 1999-10-18 | 2008-07-16 | 独立行政法人科学技術振興機構 | 眼皮膚白子症1bの原因遺伝子とその応用 |
JP4105523B2 (ja) * | 2002-10-21 | 2008-06-25 | 独立行政法人科学技術振興機構 | デルタ−サルコグリカン遺伝子の単独欠損ハムスター |
DK2332972T3 (da) * | 2003-06-24 | 2018-04-23 | Genzyme Corp | Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf |
GB0509965D0 (en) | 2005-05-17 | 2005-06-22 | Ml Lab Plc | Improved expression elements |
-
2004
- 2004-06-24 DK DK10186322.3T patent/DK2332972T3/da active
- 2004-06-24 ES ES10186322.3T patent/ES2665493T3/es not_active Expired - Lifetime
- 2004-06-24 US US10/874,242 patent/US7423135B2/en active Active
- 2004-06-24 BR BRPI0411843A patent/BRPI0411843B8/pt active IP Right Grant
- 2004-06-24 CN CN201611041276.XA patent/CN107058313A/zh active Pending
- 2004-06-24 EP EP04776236.4A patent/EP1639112B1/en not_active Revoked
- 2004-06-24 DK DK04776236.4T patent/DK1639112T3/da active
- 2004-06-24 CA CA002530020A patent/CA2530020A1/en not_active Abandoned
- 2004-06-24 EP EP17205029.6A patent/EP3346010A1/en active Pending
- 2004-06-24 WO PCT/US2004/017422 patent/WO2005000888A2/en active Application Filing
- 2004-06-24 PL PL10186322T patent/PL2332972T3/pl unknown
- 2004-06-24 JP JP2006517171A patent/JP4917886B2/ja not_active Expired - Lifetime
- 2004-06-24 SI SI200432437T patent/SI2332972T1/en unknown
- 2004-06-24 PT PT101863223T patent/PT2332972T/pt unknown
- 2004-06-24 ES ES04776236.4T patent/ES2541136T3/es not_active Expired - Lifetime
- 2004-06-24 HU HUE04776236A patent/HUE025374T2/hu unknown
- 2004-06-24 CN CN2010101456155A patent/CN101942442B/zh not_active Expired - Lifetime
- 2004-06-24 CN CN2010101456282A patent/CN101942443A/zh active Pending
- 2004-06-24 HU HUE10186322A patent/HUE036449T2/hu unknown
- 2004-06-24 EP EP10186322.3A patent/EP2332972B1/en not_active Expired - Lifetime
- 2004-06-24 CN CN2004800179482A patent/CN1813066B/zh not_active Expired - Lifetime
- 2004-06-24 CN CN201210408569.2A patent/CN103173447B/zh not_active Expired - Lifetime
-
2005
- 2005-12-18 IL IL172653A patent/IL172653A0/en active IP Right Grant
-
2008
- 2008-07-15 US US12/173,705 patent/US8829176B2/en active Active
-
2010
- 2010-09-10 JP JP2010202719A patent/JP5646927B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-16 IL IL219838A patent/IL219838A/en active IP Right Grant
-
2014
- 2014-08-01 US US14/449,628 patent/US9920318B2/en not_active Expired - Lifetime
-
2016
- 2016-03-07 IL IL244477A patent/IL244477B/en active IP Right Grant
-
2017
- 2017-11-10 US US15/809,415 patent/US10273479B2/en not_active Expired - Lifetime
-
2018
- 2018-04-10 CY CY20181100388T patent/CY1121580T1/el unknown
-
2019
- 2019-03-12 US US16/351,082 patent/US20190300880A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1639112T3 (da) | Hidtil ukendte beta-actin- og rps21-promotorer og anvendelser deraf | |
CA2554380C (en) | Mecp2e1 gene | |
EP0578909B1 (en) | Human prohibitin and DNA coding for the same | |
US7879982B2 (en) | 19.5 polypeptide antibodies useful for diagnosing or treating psoriasis | |
AU710551B2 (en) | Nucleic acid encoding a nervous tissue sodium channel | |
CA2367468C (en) | Rheumatoid arthritis gene and method for diagnosing rheumatoid arthritis | |
EP0729975B9 (en) | Ecdn protein and dna coding for the same | |
EP0905239B1 (en) | Gene encoding Afadin-1 | |
Nakane et al. | Molecular cloning and expression of HRLRRP, a novel heart-restricted leucine-rich repeat protein | |
JPWO2003076622A1 (ja) | プレシナプス蛋白p120 | |
JPH07250684A (ja) | 核酸断片及び該断片発現のためのプラスミドベクター | |
JPH09107971A (ja) | 遺伝子探索方法 | |
CA2285605A1 (en) | Fanconi-gene ii |